In 2023, Germany led the European sales of modulators of the genital system and sex hormones with 399.2 million Euros, showing a modest growth of 1.23%. Spain followed with 99.5 million Euros, but experienced a decrease of 1.18%. Finland, Greece, and Austria also declined by 2.74%, 2.22%, and 1.36% respectively.
Higher positive growth was observed in Latvia with a 3.13% increase, while Slovenia faced the largest decline at 4.64%. Growth in Luxembourg was modest at 1.01%. Despite these variations, the sector has faced overall stagnation, with fluctuations specific to country trends.
Looking ahead, factors such as aging populations and increasing investment in healthcare innovation could drive demand. Close attention should be paid to regulatory changes and emerging technologies that may impact market dynamics in the coming years.
Top countries in Modulators of the Genital System and Sex Hormones Sales by Country
| # | 9 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 399.2 | 2023 | 0% | +1.23% | View data |
| 2 | 2 Spain | 99.5 | 2023 | -12.64% | -1.18% | View data |
| 3 | 3 Finland | 50.3 | 2023 | 0% | -2.74% | View data |
| 4 | 4 Greece | 37 | 2023 | -2.63% | -2.22% | View data |
| 5 | 5 Slovakia | 17.8 | 2023 | +1.71% | -0.55% | View data |
| 6 | 6 Austria | 11.3 | 2023 | -1.74% | -1.36% | View data |
| 7 | 7 Latvia | 7.7 | 2023 | -4.94% | +3.13% | View data |
| 8 | 8 Slovenia | 5.6 | 2023 | -5.08% | -4.64% | View data |
| 9 | 9 Luxembourg | 4.1 | 2023 | 0% | +1.01% | View data |
